{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T03:32:46Z","timestamp":1769571166002,"version":"3.49.0"},"reference-count":131,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:p>The Omicron variant of SARS-CoV-2 has rapidly become the dominant strain worldwide due to its high transmissibility, although it appears to be less pathogenic than previous strains. However, individuals with hematological malignancy (HM) and COVID-19 remain susceptible to severe infection and mortality, especially those with chronic lymphocytic leukemia (CLL) and those undergoing chimeric antigen receptor T-cell (CAR-T) treatment. Hematologists should thoroughly assess the severity of the patient\u2019s hematological disease and the potential risk of SARS-CoV-2 infection before initiating chemotherapy or immunosuppressive treatment. Vaccination and booster doses are strongly recommended and patients with a poor vaccine response may benefit from long-acting COVID-19 neutralizing monoclonal antibodies (such as Evusheld). Early use of small molecule antiviral drugs is recommended for managing mild COVID-19 in HM patients and those with severe immunodeficiency may benefit from SARS-CoV-2 neutralizing monoclonal antibody therapy and high-titer COVID-19 convalescent plasma (CCP). For moderate to severe cases, low-dose glucocorticoids in combination with early antiviral treatment can be administered, with cytokine receptor antagonists or JAK inhibitors added if the condition persists or worsens. In the treatment of hematological malignancies, delaying chemotherapy is preferable for CLL, acute leukemia (AL), and low-risk myelodysplastic syndrome (MDS), but if the disease progresses, appropriate adjustments in dosage and frequency of treatment are required, with the avoidance of anti-CD20 monoclonal antibody, CAR-T and hematopoietic stem cell transplantation (HSCT). Patients with chronic myelocytic leukemia (CML) and myeloproliferative neoplasms (MPNs) can continue current treatment. What\u2019s more, non-drug protective measures, the development of new vaccines and antiviral drugs, and monitoring of mutations in immunocompromised populations are particularly important.<\/jats:p>","DOI":"10.3389\/fcimb.2023.1207225","type":"journal-article","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T08:24:47Z","timestamp":1697703887000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Omicron related COVID-19 prevention and treatment measures for patients with hematological malignancy and strategies for modifying hematologic treatment regimes"],"prefix":"10.3389","volume":"13","author":[{"given":"Wenjing","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yizhou","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sizhou","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ccell.2021.01.001","article-title":"Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients","volume":"39","author":"Abdul-Jawad","year":"2021","journal-title":"Cancer Cell"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1093\/jac\/dkad105","article-title":"Current outcomes of SARS-CoV-2 Omicron variant infection in high-risk haematological patients treated early with antivirals","volume":"78","author":"Aiello","year":"2023","journal-title":"J. Antimicrobial Chemotherapy"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.23863","article-title":"SARS-CoV-2 omicron variant in patients with chronic myeloid leukemia: A retrospective study","volume":"14","author":"Ali","year":"2022","journal-title":"Cureus"},{"key":"B4","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1159\/000525750","article-title":"Severe acute respiratory syndrome coronavirus 2 omicron variant in patients with philadelphia-negative myeloproliferative neoplasm: A single center experience","volume":"100","author":"Ali","year":"2022","journal-title":"Oncology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/s41409-020-01084-x","article-title":"COVID-19 in hematopoietic cell transplant recipients","volume":"56","author":"Altuntas","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"B6","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S2213-2600(21)00237-X","article-title":"Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial","volume":"9","author":"Aman","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"B7","unstructured":"COVID-19 and CLL: frequently asked questions"},{"key":"B8","unstructured":"COVID-19 and myelodysplastic syndromes: frequently asked questions"},{"key":"B9","unstructured":"COVID-19 and acute myeloid leukemia: frequently asked questions2022"},{"key":"B10","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41375-020-01107-y","article-title":"High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib","volume":"35","author":"Barbui","year":"2021","journal-title":"Leukemia"},{"key":"B11","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.1002\/jmv.26886","article-title":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroconversion in hematology-oncology patients","volume":"93","author":"Bird","year":"2021","journal-title":"J. Med. Virol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"E312","DOI":"10.1002\/ajh.26626","article-title":"Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological Malignancies: An EPICOVIDEHA survey report","volume":"97","author":"Blennow","year":"2022","journal-title":"Am. J. Hematol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1002\/ijc.34442","article-title":"Molnupiravir is effective in patients with haematological Malignancies","volume":"153","author":"Bo\u0142kun","year":"2023","journal-title":"Int. J. Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1177\/03000605221082875","article-title":"Special case of a patient in the blast phase of chronic myeloid leukemia successfully treated with tocilizumab during critical SARS-CoV-2 infection","volume":"50","author":"Bouchlarhem","year":"2022","journal-title":"J. Int. Med. Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.ccell.2022.04.015","article-title":"COVID-19 in patients with lymphoproliferative diseases during the Omicron variant surge","volume":"40","author":"Bronstein","year":"2022","journal-title":"Cancer Cell"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1182\/bloodadvances.2021005616","article-title":"COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP","volume":"6","author":"Busca","year":"2022","journal-title":"Blood Adv."},{"key":"B17","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41586-022-04980-y","article-title":"BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection","volume":"608","author":"Cao","year":"2022","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","first-page":"5069","DOI":"10.1002\/cncr.33160","article-title":"Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID-19","volume":"126","author":"Cattaneo","year":"2020","journal-title":"Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/hon.3064","article-title":"High mortality in fully vaccinated hematologic patients treated with anti-CD20 antibodies during the \u201cOmicron wave\u201d of COVID-19 pandemic","volume":"41","author":"Cattaneo","year":"2023","journal-title":"Hematological Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/s41375-022-01578-1","article-title":"Recommendations for the management of COVID-19 in patients with haematological Malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9)","volume":"36","author":"Cesaro","year":"2022","journal-title":"Leukemia"},{"key":"B21","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1097\/PPO.0000000000000535","article-title":"COVID-19 and chronic lymphocytic leukemia: where we stand now","volume":"27","author":"Chatzikonstantinou","year":"2021","journal-title":"Cancer J. (Sudbury Mass.)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"3444","DOI":"10.1038\/s41375-021-01450-8","article-title":"COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study","volume":"35","author":"Chatzikonstantinou","year":"2021","journal-title":"Leukemia"},{"key":"B23","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1158\/2159-8290.CD-20-0422","article-title":"Patients with cancer appear more vulnerable to SARS-CoV-2: A multicenter study during the COVID-19 outbreak","volume":"10","author":"Dai","year":"2020","journal-title":"Cancer Discovery"},{"key":"B24","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s11912-021-01169-w","article-title":"What do we currently know about chronic myeloid leukemia (CML) and COVID-19","volume":"24","author":"Delgado","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"B25","doi-asserted-by":"publisher","first-page":"4252","DOI":"10.3390\/cancers14174252","article-title":"Improved survival of lymphoma patients with COVID-19 in the modern treatment and vaccination era","volume":"14","author":"Della Pia","year":"2022","journal-title":"Cancers"},{"key":"B26","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.jtct.2022.09.002","article-title":"Revised guidelines for coronavirus disease 19 management in hematopoietic cell transplantation and cellular therapy recipients (August 2022)","volume":"28","author":"Dioverti","year":"2022","journal-title":"Transplant. Cell. Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S2213-2600(22)00006-6","article-title":"Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial","volume":"10","author":"Ely","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1038\/s43018-021-00274-w","article-title":"Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study","volume":"2","author":"Fendler","year":"2021","journal-title":"Nat. Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1053\/j.ajkd.2022.01.001","article-title":"Special considerations for paxlovid treatment among transplant recipients with SARS-CoV-2 infection","volume":"79","author":"Fishbane","year":"2022","journal-title":"Am. J. Kidney Diseases: Off. J. Natl. Kidney Foundation"},{"key":"B30","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/bjh.17027","article-title":"Clinical outcomes and risk factors for severe COVID-19 in patients with haematological disorders receiving chemo- or immunotherapy","volume":"191","author":"Fox","year":"2020","journal-title":"Br. J. Haematology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1182\/blood.2020006216","article-title":"Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19","volume":"136","author":"Frigault","year":"2020","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s13045-020-00970-7","article-title":"Impact of hematologic Malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study","volume":"13","author":"Garc\u00eda-Su\u00e1rez","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1056\/NEJMoa2116846","article-title":"Early remdesivir to prevent progression to severe Covid-19 in outpatients","volume":"386","author":"Gottlieb","year":"2022","journal-title":"New Engl. J. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.ccell.2021.09.001","article-title":"Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic Malignancies","volume":"39","author":"Greenberger","year":"2021","journal-title":"Cancer Cell"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1001\/jamaoncol.2022.3227","article-title":"Antibody response in immunocompromised patients with hematologic cancers who received a 3-dose mRNA-1273 vaccination schedule for COVID-19","volume":"8","author":"Haggenburg","year":"2022","journal-title":"JAMA Oncol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"New Engl. J. Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19","volume":"384","author":"Horby","year":"2021","journal-title":"New Engl. J. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41375-022-01511-6","article-title":"Convalescent plasma improves overall survival in patients with B-cell lymphoid Malignancy and COVID-19: a longitudinal cohort and propensity score analysis","volume":"36","author":"Hueso","year":"2022","journal-title":"Leukemia"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e393","DOI":"10.1016\/S2665-9913(20)30164-8","article-title":"Anakinra for severe forms of COVID-19: a cohort study","volume":"2","author":"Huet","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41586-022-04479-6","article-title":"SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo","volume":"603","author":"Hui","year":"2022","journal-title":"Nature"},{"key":"B41","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41586-022-04594-4","article-title":"Antibody evasion properties of SARS-CoV-2 Omicron sublineages","volume":"604","author":"Iketani","year":"2022","journal-title":"Nature"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05514-2","article-title":"Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir","author":"Iketani","year":"2022","journal-title":"Nature"},{"key":"B43","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1056\/NEJMc2214302","article-title":"Efficacy of antiviral agents against omicron subvariants BQ.1.1 and XBB","volume":"388","author":"Imai","year":"2023","journal-title":"New Engl. J. Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"e198","DOI":"10.1111\/bjh.16979","article-title":"Ruxolitinib for tocilizumab-refractory severe COVID-19 infection","volume":"190","author":"Innes","year":"2020","journal-title":"Br. J. Haematology"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00599-w","article-title":"Outcomes of patients with hematologic Malignancies and COVID-19 from the Hematologic Cancer Registry of India","volume":"12","author":"Jain","year":"2022","journal-title":"Blood Cancer J."},{"key":"B46","doi-asserted-by":"publisher","first-page":"366.e1","DOI":"10.1016\/j.jtct.2022.04.017","article-title":"Immune responses to SARS-CoV-2 vaccination in young patients with anti-CD19 chimeric antigen receptor T cell-induced B cell aplasia","volume":"28","author":"Jarisch","year":"2022","journal-title":"Transplant. Cell. Ther."},{"key":"B47","doi-asserted-by":"publisher","first-page":"4720","DOI":"10.3390\/cancers14194720","article-title":"Remdesivir decreases mortality in COVID-19 patients with active malignancy","volume":"14","author":"Jaroszewicz","year":"2022","journal-title":"Cancers"},{"key":"B48","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients","volume":"386","author":"Jayk Bernal","year":"2022","journal-title":"New Engl. J. Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1200\/JCO.20.01307","article-title":"Chemotherapy and COVID-19 outcomes in patients with cancer","volume":"38","author":"Jee","year":"2020","journal-title":"J. Clin. Oncology: Off. J. Am. Soc. Clin. Oncol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s13045-022-01387-0","article-title":"Pre-exposure prophylaxis with tixagevimab\/cilgavimab (AZD7442) prevents severe SARS-CoV-2 infection in recipients of allogeneic hematopoietic stem cell transplantation during the Omicron wave: a multicentric retrospective study of SFGM-TC","volume":"15","author":"Jondreville","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1002\/phar.2438","article-title":"Baricitinib: A review of pharmacology, safety, and emerging clinical experience in COVID-19","volume":"40","author":"Jorgensen","year":"2020","journal-title":"Pharmacotherapy"},{"key":"B52","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/tme.12915","article-title":"Convalescent plasma and COVID-19: Time for a second-second look","volume":"33","author":"Joyner","year":"2022","journal-title":"Transfusion Med. (Oxford England)"},{"key":"B53","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41594-021-00651-0","article-title":"Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis","volume":"28","author":"Kabinger","year":"2021","journal-title":"Nat. Struct. Mol. Biol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with Covid-19","volume":"384","author":"Kalil","year":"2021","journal-title":"New Engl. J. Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.6002\/ect.2022.0225","article-title":"Risk of mortality in bone marrow transplant patients during SARS-CoV-2 infection: A systematic review","volume":"21","author":"Karhana","year":"2023","journal-title":"Exp. Clin. Transplantation: Off. J. Middle East Soc. For Organ Transplant."},{"key":"B56","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1080\/10428194.2022.2086249","article-title":"Characteristics of SARS-CoV-2 infection in lymphoma\/chronic lymphocytic leukemia patients during the Omicron outbreak","volume":"63","author":"Kohn","year":"2022","journal-title":"Leukemia Lymphoma"},{"key":"B57","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1111\/ejh.13480","article-title":"Favorable COVID-19 course despite significant comorbidities in a ruxolitinib-treated patient with primary myelofibrosis","volume":"105","author":"Koschmieder","year":"2020","journal-title":"Eur. J. Haematology"},{"key":"B58","doi-asserted-by":"publisher","first-page":"5512","DOI":"10.3390\/cancers14225512","article-title":"Efficacy of COVID-19 booster vaccines in patients with hematologic Malignancies: experiences in a real-world scenario","volume":"14","author":"Krekeler","year":"2022","journal-title":"Cancers"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/S0140-6736(20)31187-9","article-title":"Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study","volume":"395","author":"Kuderer","year":"2020","journal-title":"Lancet (London England)"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1038\/s41591-021-01499-z","article-title":"Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial","volume":"27","author":"Kyriazopoulou","year":"2021","journal-title":"Nat. Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/S0140-6736(20)31173-9","article-title":"COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study","volume":"395","author":"Lee","year":"2020","journal-title":"Lancet (London England)"},{"key":"B62","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.ccell.2022.02.012","article-title":"Impact of COVID-19 on case fatality rate of patients with cancer during the Omicron wave","volume":"40","author":"Lee","year":"2022","journal-title":"Cancer Cell"},{"key":"B63","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S1470-2045(22)00202-9","article-title":"Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study","volume":"23","author":"Lee","year":"2022","journal-title":"Lancet Oncol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1053\/j.seminoncol.2022.07.005","article-title":"Influence of cancer on COVID-19 incidence, outcomes, and vaccine effectiveness: A prospective cohort study of U.S. Veterans","volume":"49","author":"Leuva","year":"2022","journal-title":"Semin. In Oncol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1093\/cid\/ciac899","article-title":"AZD7442 (Tixagevimab\/cilgavimab) for post-exposure prophylaxis of symptomatic COVID-19","volume":"76","author":"Levin","year":"2022","journal-title":"Clin. Infect. Diseases: an Off. Publ. Infect. Dis. Soc. America"},{"key":"B66","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1080\/10428194.2021.1966782","article-title":"COVID-19 among patients with hematological Malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome","volume":"62","author":"Levy","year":"2021","journal-title":"Leukemia Lymphoma"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1080\/14787210.2022.2101448","article-title":"The burden of SARS-CoV-2 in patients receiving chimeric antigen receptor T cell immunotherapy: everything to lose","volume":"20","author":"Luque-Paz","year":"2022","journal-title":"Expert Rev. Anti-infective Ther."},{"key":"B68","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1007\/s00277-022-04924-6","article-title":"Early administration of remdesivir plus convalescent plasma therapy is effective to treat COVID-19 pneumonia in B-cell depleted patients with hematological Malignancies","volume":"101","author":"Magyari","year":"2022","journal-title":"Ann. Hematol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ejca.2022.05.029","article-title":"Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis","volume":"172","author":"Mai","year":"2022","journal-title":"Eur. J. Cancer (Oxford England: 1990)"},{"key":"B70","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3324\/haematol.2022.280847","article-title":"COVID-19 in adult acute myeloid leukemia patients: a long-term followup study from the European Hematology Association survey (EPICOVIDEHA)","volume":"108","author":"Marchesi","year":"2022","journal-title":"Haematologica"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/S2213-2600(21)00331-3","article-title":"Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial","volume":"9","author":"Marconi","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"B72","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1007\/s10238-022-00964-4","article-title":"Use of remdesivir for COVID-19 in patients with hematologic cancer","volume":"23","author":"Martin-Onra\u00ebt","year":"2022","journal-title":"Clin. Exp. Med."},{"key":"B73","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/bjh.18690","article-title":"Outcome of early treatment of SARS-CoV-2 infection in patients with haematological disorders","volume":"201","author":"Mikulska","year":"2023","journal-title":"Br. J. Haematology"},{"key":"B74","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1111\/bjh.18895","article-title":"Oral anti-viral therapy for early COVID-19 infection in patients with haematological Malignancies: A multicentre prospective cohort","volume":"202","author":"Minoia","year":"2023","journal-title":"Br. J. Haematology"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1002\/cncr.33432","article-title":"COVID-19 in patients with hematological Malignancies: Considering the role of tyrosine kinase inhibitors","volume":"127","author":"Morales-Ortega","year":"2021","journal-title":"Cancer"},{"key":"B76","doi-asserted-by":"publisher","first-page":"796.e1","DOI":"10.1016\/j.jtct.2021.07.005","article-title":"Impact of SARS-CoV-2 in hematopoietic stem cell transplantation and chimeric antigen receptor T cell therapy recipients","volume":"27","author":"Mushtaq","year":"2021","journal-title":"Transplant. Cell. Ther."},{"key":"B77","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1182\/blood.2022016147","article-title":"Patients with CLL have a lower risk of death from COVID-19 in the Omicron era","volume":"140","author":"Niemann","year":"2022","journal-title":"Blood"},{"key":"B78","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/s41409-020-0961-y","article-title":"Poor outcome in patients with acute leukemia on intensive chemotherapy and COVID-19","volume":"56","author":"N\u00fa\u00f1ez-Torr\u00f3n","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S0140-6736(22)00462-7","article-title":"Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study","volume":"399","author":"Nyberg","year":"2022","journal-title":"Lancet (London England)"},{"key":"B80","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.1002\/cncr.34354","article-title":"Seroconversion and outcomes after initial and booster COVID-19 vaccination in adults with hematologic Malignancies","volume":"128","author":"Ollila","year":"2022","journal-title":"Cancer"},{"key":"B81","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1001\/jamainternmed.2021.6850","article-title":"Efficacy and safety of COVID-19 convalescent plasma in hospitalized patients: A randomized clinical trial","volume":"182","author":"Ortigoza","year":"2022","journal-title":"JAMA Internal Med."},{"key":"B82","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13045-021-01177-0","article-title":"COVID-19 infection in adult patients with hematological Malignancies: a European Hematology Association Survey (EPICOVIDEHA)","volume":"14","author":"Pagano","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1182\/blood.2022017257","article-title":"Breakthrough COVID-19 in vaccinated patients with hematologic Malignancies: results from EPICOVIDEHA survey","volume":"140","author":"Pagano","year":"2022","journal-title":"Blood"},{"key":"B84","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.1080\/10428194.2021.1948031","article-title":"Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group","volume":"62","author":"Palanques-Pastor","year":"2021","journal-title":"Leukemia Lymphoma"},{"key":"B85","doi-asserted-by":"publisher","first-page":"e737","DOI":"10.1016\/S2352-3026(20)30251-9","article-title":"Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological Malignancies in Italy: a retrospective, multicentre, cohort study","volume":"7","author":"Passamonti","year":"2020","journal-title":"Lancet Haematology"},{"key":"B86","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/hon.3086","article-title":"Management of patients with lymphoma and COVID-19: Narrative review and evidence-based practical recommendations","volume":"41","author":"Passamonti","year":"2022","journal-title":"Hematological Oncol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"4671","DOI":"10.1007\/s10067-021-05884-4","article-title":"Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trials","volume":"40","author":"Patoulias","year":"2021","journal-title":"Clin. Rheumatol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1159\/000508199","article-title":"Treating leukemia in the time of COVID-19","volume":"144","author":"Paul","year":"2021","journal-title":"Acta Haematologica"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2295","article-title":"Efficacy and secondary infection risk of tocilizumab, sarilumab and anakinra in COVID-19 patients: A systematic review and meta-analysis","volume":"32","author":"Peng","year":"2022","journal-title":"Rev. In Med. Virol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/imj.15978","article-title":"ANZTCT position statement: COVID-19 management in haematopoietic stem cell transplant and chimeric antigen receptor T cell patients","volume":"53","author":"Perram","year":"2022","journal-title":"Internal Med. J"},{"key":"B91","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40164-020-00177-z","article-title":"Risk factors and outcome of COVID-19 in patients with hematological Malignancies","volume":"9","author":"Pi\u00f1ana","year":"2020","journal-title":"Exp. Hematol. Oncol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/S1470-2045(22)00273-X","article-title":"Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study","volume":"23","author":"Pinato","year":"2022","journal-title":"Lancet Oncol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1016\/S1470-2045(21)00573-8","article-title":"Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study","volume":"22","author":"Pinato","year":"2021","journal-title":"Lancet Oncol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1111\/bcp.15644","article-title":"Experience with Sotrovimab treatment of SARS-CoV-2 infected patients in Denmark","volume":"89","author":"Rasmussen","year":"2022","journal-title":"Br. J. Clin. Pharmacol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(22)00163-5","article-title":"Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"399","year":"2022","journal-title":"Lancet (London England)"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"397","year":"2021","journal-title":"Lancet (London England)"},{"key":"B97","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S0140-6736(22)01109-6","article-title":"Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis","volume":"400","year":"2022","journal-title":"Lancet (London England)"},{"key":"B98","doi-asserted-by":"publisher","first-page":"5951","DOI":"10.1182\/bloodadvances.2022008932","article-title":"Vaccine-boosted convalescent plasma therapy for patients with immunosuppression and COVID-19","volume":"6","author":"Ripoll","year":"2022","journal-title":"Blood Adv."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1182\/blood.2021011841","article-title":"COVID-19 in patients with CLL: improved survival outcomes and update on management strategies","volume":"138","author":"Roeker","year":"2021","journal-title":"Blood"},{"key":"B100","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1093\/cid\/ciac180","article-title":"Molnupiravir and nirmatrelvir-ritonavir: oral coronavirus disease 2019 antiviral drugs","volume":"76","author":"Saravolatz","year":"2023","journal-title":"Clin. Infect. Diseases: an Off. Publ. Infect. Dis. Soc. America"},{"key":"B101","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1038\/s41375-020-0959-x","article-title":"COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus","volume":"34","author":"Scarf\u00f2","year":"2020","journal-title":"Leukemia"},{"key":"B102","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1111\/bjh.18315","article-title":"Treatment with obinutuzumab leads to worse outcomes in haematological patients diagnosed with Omicron variant COVID-19","volume":"198","author":"Shafat","year":"2022","journal-title":"Br. J. Haematology"},{"key":"B103","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1007\/s11864-022-00975-z","article-title":"How the COVID-19 pandemic reshaped the management of leukemia and affected patient outcomes","volume":"23","author":"Sharafeldin","year":"2022","journal-title":"Curr. Treat Options In Oncol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"e185","DOI":"10.1016\/S2352-3026(20)30429-4","article-title":"Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study","volume":"8","author":"Sharma","year":"2021","journal-title":"Lancet Haematology"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1111\/imj.15954","article-title":"Low mortality in vaccinated immunocompromised haematology patients infected with SARS-CoV-2","volume":"52","author":"Shaw","year":"2022","journal-title":"Internal Med. J"},{"key":"B106","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1158\/2643-3230.BCD-21-0222","article-title":"CD20-targeted therapy ablates de novo antibody response to vaccination but spares preestablished immunity","volume":"3","author":"Shree","year":"2022","journal-title":"Blood Cancer Discov."},{"key":"B107","doi-asserted-by":"publisher","first-page":"545","DOI":"10.15585\/mmwr.mm7115e1","article-title":"COVID-19 mortality and vaccine coverage - Hong Kong special administrative region, China, january 6, 2022-march 21, 2022","volume":"71","author":"Smith","year":"2022","journal-title":"MMWR. Morbidity Mortality Weekly Rep."},{"key":"B108","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1200\/JCO.21.02419","article-title":"Risk and outcome of breakthrough COVID-19 infections in vaccinated patients with cancer: real-world evidence from the national COVID cohort collaborative","volume":"40","author":"Song","year":"2022","journal-title":"J. Clin. Oncology: Off. J. Am. Soc. Clin. Oncol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"14(656)","DOI":"10.1126\/scitranslmed.abo0718","article-title":"Mutations in the SARS-CoV-2 RNA-dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms","author":"Stevens","year":"2022","journal-title":"Sci. Trans. Med."},{"key":"B110","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.ccell.2022.05.007","article-title":"Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic Malignancies","volume":"40","author":"Stuver","year":"2022","journal-title":"Cancer Cell"},{"key":"B111","doi-asserted-by":"publisher","first-page":"6478","DOI":"10.1038\/s41467-022-33864-y","article-title":"Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources","volume":"13","author":"Sullivan","year":"2022","journal-title":"Nat. Commun."},{"key":"B112","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1007\/s00277-022-04833-8","article-title":"Infections with the SARS-CoV-2 Omicron variant show a similar outcome as infections with the previous variants in patients with hematologic Malignancies","volume":"101","author":"Taenaka","year":"2022","journal-title":"Ann. Hematol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1056\/NEJMc2207519","article-title":"Efficacy of antibodies and antiviral drugs against omicron BA.2.12.1, BA.4, and BA.5 subvariants","volume":"387","author":"Takashita","year":"2022","journal-title":"New Engl. J. Med."},{"key":"B114","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1001\/jamaoncol.2021.1799","article-title":"Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19","volume":"7","author":"Thompson","year":"2021","journal-title":"JAMA Oncol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1182\/blood.2021012248","article-title":"COVID-19 convalescent plasma","volume":"140","author":"Tobian","year":"2022","journal-title":"Blood"},{"key":"B116","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1016\/j.cell.2022.06.005","article-title":"Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum","volume":"185","author":"Tuekprakhon","year":"2022","journal-title":"Cell"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2022.105252","article-title":"Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern","volume":"198","author":"Vangeel","year":"2022","journal-title":"Antiviral Res."},{"key":"B118","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/s41375-020-01018-y","article-title":"Compassionate use of JAK1\/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study","volume":"35","author":"Vannucchi","year":"2021","journal-title":"Leukemia"},{"key":"B119","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1038\/s41375-020-01019-x","article-title":"COVID-19 infection in hematopoietic cell transplantation: age, time from transplant and steroids matter","volume":"34","author":"Varma","year":"2020","journal-title":"Leukemia"},{"key":"B120","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1182\/blood.2020008824","article-title":"Outcomes of patients with hematologic Malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients","volume":"136","author":"Vijenthira","year":"2020","journal-title":"Blood"},{"key":"B121","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s00210-022-02265-9","article-title":"Pandemic COVID-19, an update of current status and new therapeutic strategies","volume":"395","author":"Vitiello","year":"2022","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"B122","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1001\/jamaoncol.2020.6178","article-title":"Analyses of risk, racial disparity, and outcomes among US patients with cancer and COVID-19 infection","volume":"7","author":"Wang","year":"2021","journal-title":"JAMA Oncol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/hon.2974","article-title":"Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients - A Czech multicenter experience","volume":"40","author":"Weinbergerov\u00e1","year":"2022","journal-title":"Hematological Oncol."},{"key":"B124","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1016\/S0140-6736(22)00519-0","article-title":"Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses","volume":"399","year":"2022","journal-title":"Lancet (London England)"},{"key":"B125","doi-asserted-by":"publisher","first-page":"5966","DOI":"10.1182\/bloodadvances.2020003170","article-title":"Outcomes of patients with hematologic Malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub","volume":"4","author":"Wood","year":"2020","journal-title":"Blood Adv."},{"key":"B126","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1093\/cid\/ciac916","article-title":"Predictors of COVID-19 hospitalization after sotrovimab in hematologic Malignancy patients during the BA.1 Omicron surge","volume":"76","author":"Yan","year":"2022","journal-title":"Clin. Infect. Diseases: an Off. Publ. Infect. Dis. Soc. America"},{"key":"B127","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1002\/jmv.26404","article-title":"The outcome of COVID-19 in patients with hematological Malignancy","volume":"93","author":"Yigenoglu","year":"2021","journal-title":"J. Med. Virol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1126\/science.abn8939","article-title":"Pathogenicity, transmissibility, and fitness of SARS-CoV-2 Omicron in Syrian hamsters","volume":"377","author":"Yuan","year":"2022","journal-title":"Sci. (New York N.Y.)"},{"key":"B129","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.3390\/v14112377","article-title":"Patients with hematological Malignancies treated with T-cell or B-cell immunotherapy remain at high risk of severe forms of COVID-19 in the omicron era","volume":"14","author":"Zerbit","year":"2022","journal-title":"Viruses"},{"key":"B130","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1182\/bloodadvances.2020001907","article-title":"First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab","volume":"4","author":"Zhang","year":"2020","journal-title":"Blood Adv."},{"key":"B131","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/bjh.18823","article-title":"COVID-19 infection in patients with haematological Malignancies: A single-centre survey in the latest Omicron wave in China","volume":"202","author":"Zhu","year":"2023","journal-title":"Br. J. Haematology"}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2023.1207225\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T08:25:25Z","timestamp":1697703925000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2023.1207225\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,19]]},"references-count":131,"alternative-id":["10.3389\/fcimb.2023.1207225"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2023.1207225","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,19]]},"article-number":"1207225"}}